CLINICAL ROLE -
First Oral Tablet for Chemotherapy-induced Diarrhea in Dogs Receives Conditional FDA Approval
The prescription-only crofelemer delayed-release tablets were developed using a sustainable, plant-based formula.
Read More
Improving Adherence to Oral Oncolytics
Multiple strategies can be used to create an individualized approach to therapies and removing barriers for patients with cancer.
New Data Show Promise for Patient Outcomes With Capmatinib
The kinase inhibitor is a promising treatment option for patients with MET exon 14 skipping mutation non–small cell lung cancer.
FDA Committee Votes to Recommend New Johnson & Johnson COVID-19 Vaccine for EUA
In voting in favor of the recommendation, 22 committee members unanimously agreed that the benefits of the Johnson & Johnson COVID-19 vaccine outweigh its risks.
FDA Oks Gene Therapy for Children with Spinal Muscular Atrophy
The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.
Lawmakers Deny Proposal to Require Drug Pricing in Television Ads
A federal appropriations bill will not include bipartisan provision that would have required drug manufacturers to be more transparent with costs to consumers after it was blocked by House Republicans.
FDA OKs First Generic of Drug Used to Treat Opioid Dependence
FDA officials have approved the first generic versions of buprenorphine and naloxone (Suboxone, Mylan Technologies Inc and Dr. Reddy's Laboratories SA) sublingual film to treat opioid dependence.
FDA Approves First Generic of Drug Used to Treat Opioid Dependence
Agency officials have given the green light to versions of buprenorphine and naloxone (Suboxone, Mylan Technologies Inc and Dr. Reddy's Laboratories SA) sublingual film.
FDA Approves Treatment for Moderate-to-Severe Plaque Psoriasis
The FDA has approved ILUMYA (tildrakizumab-asmn, Sun Pharma) for treating adults with moderate-to-severe plaque psoriasis.
